Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients

Clinical Transplantation

Volumn 26, Issue 6, 2012, Pages 849-852

  Sun, Hsin Yun ^a,b   Wagener, Marilyn ^b,c   Cacciarelli, Thomas V ^b,c   Singh, Nina ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Early post transplant Infections; Hepatic encephalopathy; Liver transplant; Multidrug resistant bacteria; Rifaximin

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; COTRIMOXAZOLE; METHYLPREDNISOLONE; MICAFUNGIN; RIFAXIMIN; TACROLIMUS;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOSIS; PNEUMOCYSTOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SURVIVAL RATE;

AGED; ANTI-INFECTIVE AGENTS; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPATIC ENCEPHALOPATHY; HUMANS; INFECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RIFAMYCINS; RISK FACTORS; SURVIVAL RATE;

EID: 84870683317     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01619.x     Document Type: Article

References (17)

1. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005: 3: 201.
2. Huang DB, DuPont HL. Rifaximin-a novel antimicrobial for enteric infections. J Infect 2005: 50: 97.
3. Alvisi V, Tralli M, Loponte A, Pavani F, Massari M. [Double-blind study of treatment with SF 68 or with antibiotics in acute enteritis in adults]. Clin Ter 1982: 101: 581.
4. Della Marchina M, Renzi G, Palazzini E. Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Chemioterapia 1988: 7: 336.
5. Giacometti A, Ferrieri A, Cirioni O. Treatment of diarrhea in AIDS patients: double-blind clinical trial. Farmaci&Terapia Int J Drugs Ther 1993: 10: 107.
6. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995: 9: 33.
7. Giaccari S, Tronci S, Falconieri M, Ferrieri A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Riv Eur Sci Med Farmacol 1993: 15: 29.
8. Scalco GB, Rossi MR, Rubbini M, Cirelli C. Rifaximin: a new rifamycin for the prophylaxis of the septic complications in the large bowel surgery. Policlinico Sez Chir 1987: 94: 41.
9. Verardi S, Varardi V, Fusillo M. Rifaximin effectiveness evaluation in the preparation of large intestine to surgery. Eur Rev Med Pharmacol Sci 1986: 8: 267.
10. Festi D, Mazzella G, Orsini M. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp 1993: 54: 598.
11. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991: 23: 175.
12. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010: 362: 1071.
13. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001: 71: 910.
14. Singh N, Gayowski T, Wagener MM. Posttransplantation dialysis-associated infections: morbidity and impact on outcome in liver transplant recipients. Liver Transpl 2001: 7: 100.
15. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004: 10: 1009.
16. DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005: 142: 805.
17. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008: 20: 186.